PharmaFocus Today – media

Anglikang Adenosylcobalamin Capsules Obtain Drug Registration Certificate

March 4th – AnglikangThe company announced that it recently obtained adenosine cobalt from the National Medical Products Administration.The company has obtained the Drug Registration Certificate for Amino Capsules. This drug is indicated for the adjunctive treatment of megaloblastic anemia, nutritional anemia, anemia of pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, nerve palsy, as well as nutritional disorders and radiation- and drug-induced leukopenia. The company received the notification of acceptance for its marketing authorization application in June 2024 and recently received approval from the National Medical Products Administration. The announcement indicates that, according to relevant national policies, obtaining the Drug Registration Certificate is considered equivalent to passing the consistency evaluation. This drug registration certificate will further enrich the company’s product pipeline; however, drug sales are easily affected by factors such as national policies and changes in the market environment, and there is considerable uncertainty regarding specific sales performance. https://finance.eastmoney.com/a/202603053663192752.html
- Source: drugdu
- 32
- March 6, 2026
Two Minoxidil Topical Solution Applications from its Subsidiary Approved

China Securities Intelligent Finance – China Pharmaceutical(600056) announced on March 6 that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., recently received two “Approval Notices for Supplementary Applications” for minoxidil liniment issued by the National Medical Products Administration, becoming the marketing authorization holder for the drug. The announcement indicates that minoxidil topical solution is a dermatology and ENT medication used to treat male pattern baldness and alopecia areata. The National Medical Products Administration (NMPA) accepted a supplementary application for a change of marketing authorization holder for this drug in January 2026, and the project has accumulated an investment of approximately 6.45 million yuan as of the date of this announcement. According to the third-party database Menet, the drug’s sales in China’s three major terminals and six major markets reached approximately 447 million yuan in 2024, and approximately 315 million yuan in the first three quarters of 2025. The company stated that ...
- Source: drugdu
- 32
- March 6, 2026
Zhejiang Medicine’s ARX305 Initiates Phase II Clinical Trial

On the evening of March 5th that Zhejiang Medicine…(600216) issued an announcement stating that its subsidiary, Zhejiang Xinma Biopharmaceutical Co., Ltd. (hereinafter referred to as “Xinma Bio”), has initiated a single-arm, open-label phase II clinical study on the efficacy and safety of its injectable recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate (ARX305) for relapsed/refractory lymphoma. Zhejiang Medicine stated that the recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (ARX305) is a new generation monoclonal antibody-drug conjugate jointly developed by Newcode Biotech and Ambrx, Inc. of the United States, under a “Cooperative Development and Licensing Agreement” signed on October 22, 2019. It is used to treat advanced tumors expressing CD70 and belongs to innovative biotechnology drugs. https://finance.eastmoney.com/a/202603053663319462.html
- Source: drugdu
- 29
- March 6, 2026
Indacaterol Mometasone Inhalation Powder Clinical Trial Approved for Asthma Treatment

On March 5, CSPC Pharmaceutical Group (01093) announced that its indacaterol mometasone inhalation powder has been approved by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. This product is primarily used for maintenance treatment of asthma in adults and adolescents aged 12 and above, and has the effects of relaxing smooth muscles and dilating the bronchi. Indacaterol mometasone inhaler powder is the first once-daily ICS-LABA combination inhaler included in the National Medical Insurance Catalog (2022 Edition), providing asthma patients with a more efficient and convenient treatment option. https://finance.eastmoney.com/a/202603053663314598.html
- Source: drugdu
- 29
- March 6, 2026
Harsco Pharmaceutical’s innovative drug HSK50042 tablets receive clinical approval for a new indication

on the evening of March 5th that Harsco Pharmaceutical…(002653) issued an announcement stating that its subsidiary, Shanghai Haishengnuo Pharmaceutical Technology Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, with the indication being respiratory diseases. Harsco Pharmaceuticals stated that HSK50042 tablets are an orally administered, potent, and highly selective small molecule inhibitor independently developed by the company. This latest approval for a new indication in the field of respiratory diseases marks another significant milestone in its clinical trials. Preclinical studies have shown that HSK50042 can effectively improve the pathological symptoms of lung diseases in model mice at relatively low doses, demonstrating good efficacy, good tolerability, and a large safety window. It is a drug with great development potential and is expected to provide patients with respiratory diseases with a highly effective and safe new treatment option. https://finance.eastmoney.com/a/202603053663302749.html
- Source: drugdu
- 28
- March 6, 2026
Clinical trial application for HLX97 approved by the National Medical Products Administration

On March 5th, Henlius Biotech (02696.HK) issued a voluntary announcement stating that its Investigational New Drug (IND) application for HLX97 (a small molecule inhibitor of KAT6A/B), developed independently, in patients with advanced/metastatic solid tumors, has been approved by the National Medical Products Administration (NMPA). HLX97 is a small molecule inhibitor targeting the lysine acetyltransferase KAT6A/B. Non-clinical studies have shown that it has good anti-tumor efficacy and safety characteristics; currently, there are no similar KAT6A/B small molecule inhibitors approved for marketing globally. This progress marks an important milestone in the company’s innovative oncology treatment pipeline, and clinical research will proceed as planned. Given the long development cycle, high investment, and high risk of new drug development, the company cautions that it cannot guarantee the ultimate successful development and commercialization of HLX97, and investors are advised to be aware of the investment risks. 网址：https://finance.eastmoney.com/a/202603053663239623.html
- Source: drugdu
- 29
- March 6, 2026
Eli Lilly wins another victory! Regcizosumab submits its marketing application in China

On March 3, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China showed that Eli Lilly and Company’s application for marketing authorization of its Class 3.1 new drug, Lerechizumab injection, has been accepted.Lebrikizumab is an interleukin-13 (IL-13) inhibitor that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate. The binding site of lebrikizumab to the IL-13 cytokine overlaps with the binding site of the IL-4Rα subunit in the IL-13Rα1/IL-4Rα heterodimer, thereby preventing the formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is a major cytokine in atopic dermatitis, driving type 2 inflammation in the skin, leading to skin barrier dysfunction, itching, skin thickening, and infection.The development of lericizumab has been a long and winding road. Originally developed by Roche, the drug began its first clinical trial in 2008, but its initial indication of asthma ...
- Source: drugdu
- 38
- March 5, 2026
Henlius’s potential best-in-class small molecule drug receives its first clinical trial approval

On March 4, the CDE (Center for Drug Evaluation) website showed that Henlius’ HLX97 clinical trial application was approved for the treatment of advanced/metastatic solid tumors. This is the third domestically produced KAT6A/B inhibitor to receive clinical trial approval. Source: CDE Official Website HLX97 is a novel, potentially best-in-class oral histone acetyltransferase (KAT6A/B) inhibitor . KAT6A/B is a highly promising target for the treatment of solid tumors such as breast cancer, and its abnormalities are closely associated with the development and progression of various hematologic malignancies and solid tumors. HLX97 regulates the proliferation, differentiation, and apoptosis of tumor cells by precisely inhibiting the activity of KAT6A/B. It has pharmacokinetic characteristics of rapid onset and rapid clearance and high selectivity. It aims to maximize the anti-tumor activity of the drug while reducing the blood toxicity of the product, and is expected to bring new treatment options to patients with cancers such ...
- Source: drugdu
- 37
- March 5, 2026
New anti-aging drug approved for clinical trials

On March 2nd, RC017 , an innovative drug developed by Nanjing Ruichu Pharmaceuticals targeting the mechanisms of aging to treat eye diseases , officially received FDA approval for clinical trials in the United States. Notably, this is the first time in FDA history that a Chinese anti-aging innovative drug clinical trial application has been approved. RC017 is one of the core pipelines of Ruichu Pharmaceuticals, focusing on “targeting aging mechanisms.” The company employs a unique “three-platform R&D strategy,” focusing on key biological pathways such as chronic inflammation, clearance of senescent cells, and cell reprogramming. Research shows that with age, the common molecular basis of many degenerative diseases converges on chronic inflammatory pathways, and the RC series of drugs is based on the identification and intervention of emerging first-in-class inflammation-related targets. Founded in June 2021 and headquartered in Nanjing, Ruichu Pharmaceuticals is a leading Chinese company focused on the biology of ...
- Source: drugdu
- 35
- March 5, 2026
First in the world and first in China, Yahong Pharmaceutical’s non-invasive treatment for cervical precancerous lesions, Cervita, has been approved

(China, March 3, 2026) Asarum Pharmaceuticals (stock code: 688176.SH), a global innovative pharmaceutical company focusing on urogenital tumors and women’s health, announced that its core product APL-1702 (trade name: Cevira®, generic name: Hexyl valerate hydrochloride ointment for cervical photodynamic therapy) has received a Drug Registration Certificate issued by the National Medical Products Administration of China, officially approving its market launch. This product is the world’s first non-surgical, non-invasive treatment for patients with cervical intraepithelial neoplasia grade 2 (CIN2), filling a clinical gap in this treatment area and redefining a potentially huge blue ocean market for non-invasive treatments. Currently, cervical cancer remains a major threat to women’s health worldwide. According to a 2023 market survey, the number of patients with high-grade squamous intraepithelial lesions (CIN2) diagnosed by histopathology in my country exceeds 700,000, of which approximately 60% are CIN2. It is projected that the incidence, screening rate, and diagnosis rate will ...
- Source: drugdu
- 33
- March 5, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.